Epidermal growth factor receptor inhibitors (EGFRIs) stand out as the most frequently used class of targeted agents and are widely used in the management of diverse malignancies, including lung, pancreatic, head and neck, and colorectal cancer (1). Here, EGFR is linked to colorectal cancer.